Table 2.
Biochemical parameters of NVAF patients and comparative analysis between gender and age groups.
| Characteristics | NVAF Patients, n = 150 | Comparison between Gender | Comparison between Age Groups | ||||
|---|---|---|---|---|---|---|---|
| Male, n = 90 | Female, n = 60 | p Value | Age < 65, n = 100 | Age ≥ 65, n = 50 | p Value | ||
| HGB, g/L | 141.0 ± 14.5 | 146.6 ± 12.3 | 132.7 ± 13.4 | 0.001 ** | 144.8 ± 13.8 | 133.6 ± 12.9 | 0.001 ** |
| RBC, ×1012/L | 4.77 ± 0.66 | 5.00 ± 0.71 | 4.63 ± 0.52 | 0.31 | 4.85 ± 0.71 | 4.60 ± 0.51 | 0.002 * |
| PLT, ×109/L | 255.7 ± 59.1 | 253.3 ± 62.4 | 259.3 ± 53.9 | 0.18 | 261.7 ± 58.0 | 243.7 ± 59.9 | 0.04 * |
| WBC, ×109/L | 6.37 ± 1.76 | 6.52 ± 1.79 | 6.13 ± 1.70 | 0.07 | 6.38 ± 1.73 | 6.34 ± 1.84 | 0.91 |
| CRE, mg/dL | 0.88 ± 0.17 | 0.93 ± 0.16 | 0.79 ± 0.15 | 0.001 * | 0.87 ± 0.16 | 0.88 ± 0.19 | 0.56 |
| BUN, mg/dL | 35.1 ± 9.70 | 34.8 ± 9.23 | 35.6 ± 10.4 | 0.6 | 34.9 ± 9.06 | 35.6 ± 11.0 | 0.69 |
| TBIL, mg/dL | 0.66 ± 0.28 | 0.69 ± 0.28 | 0.63 ± 0.28 | 0.13 | 0.66 ± 0.27 | 0.67 ± 0.31 | 0.99 |
| DBIL, mg/dL | 0.19 ± 0.16 | 0.17 ± 0.12 | 0.21 ± 0.20 | 0.93 | 0.18 ± 0.14 | 0.21 ± 0.20 | 0.5 |
| CL, mmol/L | 4.47 ± 1.06 | 4.38 ± 0.95 | 4.61 ± 1.20 | 0.2 | 4.46 ± 1.08 | 4.50 ± 1.01 | 0.84 |
| ALT, U/L | 21.4 ± 9.66 | 21.4 ± 8.98 | 21.4 ± 10.7 | 0.58 | 21.9 ± 9.42 | 20.2 ± 10.1 | 0.07 |
| AST, U/L | 21.3 ± 8.73 | 20.8 ± 8.08 | 22.1 ± 9.64 | 0.38 | 21.4 ± 8.22 | 21.1 ± 9.76 | 0.55 |
| PT, sec | 12.6 ± 3.09 | 12.8 ± 3.39 | 12.3 ± 2.60 | 0.53 | 12.6 ± 3.21 | 12.7 ± 2.87 | 0.56 |
| PI, % | 93.7 ± 22.1 | 92.2 ± 23.8 | 95.9 ± 19.3 | 0.33 | 94.2 ± 22.5 | 92.6 ± 21.6 | 0.5 |
| APTT, sec | 37.5 ± 7.19 | 37.2 ± 6.63 | 37.9 ± 8.00 | 0.72 | 37.7 ± 7.11 | 37.1 ± 7.42 | 0.53 |
| FBG, g/L | 3.20 ± 0.95 | 3.07 ± 0.99 | 3.40 ± 0.84 | 0.01 * | 3.26 ± 1.03 | 3.10 ± 0.75 | 0.55 |
| Dabigatran concentration, ng/mL | |||||||
| Peak | 104.6 ± 72.8 | 92.4 ± 70.3 | 122.8 ± 73.3 | 0.003 * | 106.7 ± 80.7 | 100.5 ± 54.2 | 0.6 |
| Trough | 55.6 ± 37.9 | 49.8 ± 36.2 | 64.3 ± 39.2 | 0.002 * | 53.6 ± 40.5 | 59.6 ± 32.3 | 0.05 * |
| Apixaban concentration, ng/mL | |||||||
| Peak | 164.9 ± 78.1 | 153.9 ± 68.9 | 181.4 ± 88.2 | 0.06 | 156.8 ± 73.4 | 181.3 ± 85.3 | 0.05 * |
| Trough | 101.1 ± 45.9 | 92.6 ± 39.2 | 113.9 ± 52.2 | 0.01 ** | 93.8 ± 42.1 | 115.7 ± 50.1 | 0.002 * |
Note: Continuous variables are presented, mean ± SD and categorical variables as n (%). Student’s t-test p value is marked with double asterisks (**); Mann–Whitney U test’s p-value is marked with single asterisk (*); The significant p value (p < 0.05); Abbreviations: NVAF patients, nonvalvular atrial fibrillation patients; HGB, hemoglobin; RBC, red blood cells; PLT, platelets; WBC, white blood cells; CRE, creatinine; BUN, blood urea nitrogen; TBIL, total bilirubin; DBIL, direct bilirubin; CL, cholesterol; ALT, alanine aminotransferase; AST, aspartate aminotransferase; PT, prothrombin time; PI, prothrombin index; APTT, activated partial thromboplastin time; FBG, fibrinogen.